Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Prof. Franca Fagioli)
- Development stage
- Unknown
- Lead developer
- Sant'Anna OIRM Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an investigational cell-based immunotherapy being developed by Prof. Franca Fagioli at the Sant'Anna OIRM Hospital for the treatment of advanced, relapsed, and non-resectable sarcomas. CIK cells are ex vivo expanded T lymphocytes that exhibit a mixed T-NK phenotype (CD3+CD56+) and possess potent, MHC-unrestricted antitumor activity. The cytotoxic effect is primarily mediated through the NKG2D receptor, which recognizes stress-inducible ligands such as MIC A/B and ULBPs expressed on the surface of sarcoma cells, including chemoresistant cancer stem-like cells. This therapy is currently being evaluated in Phase I clinical trials to determine the maximum tolerated dose and safety profile in pediatric and adult patients with bone and soft-tissue sarcomas.
- Other names
- Autologous CIK cellsCIK cells
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Prof. Franca Fagioli).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Prof. Franca Fagioli).